Optic Neuritis Market to Register Immense Growth During the Forecast Period (2022-2032) – DelveInsight | Key Companies – Noveome, Questcor, Biogen, Accure Therapeutics, Mitochon Pharma

 Breaking News
  • No posts were found

Optic Neuritis Market to Register Immense Growth During the Forecast Period (2022-2032) – DelveInsight | Key Companies – Noveome, Questcor, Biogen, Accure Therapeutics, Mitochon Pharma

Optic Neuritis Market to Register Immense Growth During the Forecast Period (2022-2032) - DelveInsight | Key Companies - Noveome, Questcor, Biogen, Accure Therapeutics, Mitochon Pharma
Delveinsight Business Research LLP
As per DelveInsight, the Optic neuritis therapeutics market is anticipated to evolve immensely in the coming years owing to the recent increase in research and development programs related to Optic neuritis and the expected launch of emerging therapies. Some of the key players, such as Accure Therapeutics, Mitochon Pharmaceuticals, Noveome Biotherapeutics, and others, are actively working in the Optic neuritis Market.

DelveInsight’s “Optic Neuritis Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Optic Neuritis market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The Optic Neuritis market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Optic Neuritis Market

Optic Neuritis: An Overview

Optic Neuritis (ON) is inflammation of the optic nerve due to many causes, indicated by sub-acute unilateral painful visual loss, mostly in a young and healthy female. ON is the most common optic neuropathy in persons under 50 years coming to general ophthalmic practice.

Optic Neuritis is mainly idiopathic in nature, though it could be related to demyelinating lesions (e.g., MS neuromyelitis optica (NMO)) or other less common etiologies such as autoimmune disease ([.g. sarcoidosis, systemic lupus erythematosus (SLE)], infectious and para-infectious causes (e.g., syphilis, tuberculosis), inflammatory and post-vaccination immunological responses (e.g., sinusitis, and vaccinations against measles and rubella.

Optic Neuritis Market Key Facts

  • According to the study published by Pau et al. (2011), the annual incidence of ON in the United States is estimated to be 5 to 6.4 per 100 000.

  • As per the study by Wilhelm and Schabet et al. (2015), the incidence of optic neuritis in Central Europe is 5 cases per 100 000 persons per year.

  • According to Martínez-Lapiscina et al. (2014), the mean annual incidence rate of ON was 5.36 cases per 100,000 person-years in Spain.

  • The study published by Wakakura et al. suggests that the incidence of optic neuritis in Japan is estimated to be 1.03 per 100 000 population.

Optic Neuritis Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current and forecasted Optic Neuritis market size by analyzing the impact of current and emerging pipeline therapies. It also thoroughly assesses the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the Optic Neuritis market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Optic Neuritis Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders. 

The Report Covers the Optic Neuritis Epidemiology, Segmented as –

  • Total Incidence of Optic Neuritis [2019–2032]

  • Age-specific Incidence of Optic Neuritis [2019–2032]

  • Gender-specific Incidence of Optic Neuritis [2019–2032]

  • Type-Specific Incident Population of Optic Neuritis [2019–2032]

  • Diagnosed and treatable cases of Optic Neuritis [2019–2032]

Optic Neuritis Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Optic Neuritis market or expected to be launched during the study period. The analysis covers the Optic Neuritis market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Optic Neuritis pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Optic Neuritis Market Will Evolve and Grow by 2032 @ 


Optic Neuritis Therapeutics Analysis

Novel technologies and an improved understanding of the condition and its association with Multiple Sclerosis have provided an ideal approach for renewed investigations and the development of new treatment methods for Optic Neuritis. Currently, several major pharma and biotech giants such as iogen, Mitochon Pharmaceuticals, Noveome Biotherapeutics, and others are actively working in the therapeutic domain to improve the treatment scenario. The launch of the pipeline therapies is expected to significantly impact the treatment pattern of Optic Neuritis in the upcoming years.

The Leading Companies in the Optic Neuritis Therapeutics Market Include:

  • Accure Therapeutics

  • Mitochon Pharmaceuticals

  • Noveome

  • Questcor

  • Biogen

And Many Others

Optic Neuritis Therapies Covered in the Report Include:

  • ACT-01: Accure Therapeutics

  • MP-101: Mitochon Pharmaceuticals

  • ST266: Noveome

  • H.P. Acthar Gel (repository corticotropin) Injection: Questcor

  • Opicinumab: Biogen

And Many More

The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @


Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Optic Neuritis Competitive Intelligence Analysis

4. Optic Neuritis Market Overview at a Glance

5. Optic Neuritis Disease Background and Overview

6. Optic Neuritis Patient Journey

7. Optic Neuritis Epidemiology and Patient Population (In the US, EU5, and Japan)

8. Optic Neuritis Treatment Algorithm, Current Treatment, and Medical Practices

9. Optic Neuritis Unmet Needs

10. Key Endpoints of Optic Neuritis Treatment

11. Optic Neuritis Marketed Products

12. Optic Neuritis Emerging Drugs and Latest Therapeutic Advances

13. Optic Neuritis Seven Major Market Analysis

14. Attribute Analysis

15. Optic Neuritis Market Outlook (In US, EU5, and Japan)

16. Optic Neuritis Access and Reimbursement Overview

17. KOL Views on the Optic Neuritis Market

18. Optic Neuritis Market Drivers

19. Optic Neuritis Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download the Sample PDF to Learn More About the Key Offerings of the Report @



Connect with us and discover how Delveinsight can help you to identify your potential business partners and investors in the highly dynamic and evolving pharmaceutical market today @ Pharmaceutical Partner Identification Solutions

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/